Report
Jacob Mekhael

Pharvaris 2Q25 update shows all is on track, on-demand phase 3 readout in 4Q25

Pharvaris reported 2Q25 results showing no major surprises and confirming previously communicated timelines, with the next key milestone being topline results from the phase 3 trial of deucrictibant (B2R antagonist, oral tablet) in on-demand HAE in 4Q25 – we are confident in a positive outcome. The company reported a cash position of $ 200m (YE24: $281m), which was supplemented by $ 201m in a public offering in July 2025, providing Pharvaris with a cash runway into 1H27. We continue to see Pharvaris as uniquely positioned in the HAE space, and reiterate our $ 29 TP and Buy rating.
Underlying
Pharvaris NV

Provider
KBC Securities
KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

 

Analysts
Jacob Mekhael

Other Reports on these Companies
Other Reports from KBC Securities
Guy Sips ... (+3)
  • Guy Sips
  • Livio Luyten
  • Thibault Leneeuw

ResearchPool Subscriptions

Get the most out of your insights

Get in touch